End Stage Renal Disease on Dialysis
Conditions
Keywords
Therapeutic diet, Mineral metabolism, Uremic toxins, Inflammation, Immune, End-stage kidney disease
Brief summary
Patients with end-stage kidney disease have hyperphosphatemia and accumulated uremic toxin level due to decreased urine excretion ability. Unhealthy diet causes altered mineral metabolism, elevated uremic toxin level, immune dysregulation, and inflammation. The investigators hypothesize that therapeutic diet intervention reverses altered mineral metabolism, elevated uremic toxin level, immune dysregulation, and inflammation. In this study, the investigators crafted 7-day special healthy diet to illustrate the clinical implications of therapeutic diet for dialysis patients.
Detailed description
The risk of cardiovascular disease (CVD) and mortality in patients with end-stage kidney disease (ESKD) is far greater than those in the general population. Emerging evidence suggests that unhealthy diet causes altered mineral metabolism, disturbance of gut microbiota (dysbiosis) with elevated uremic toxin level, immune dysregulation, and inflammation; these abnormalities are strongly related to development of CVD. Little is known about the relationship between therapeutic diet intervention and cardiovascular risk in patients with ESKD. Recently, the study of the investigators showed that ESKD patients undergoing hemodialysis who consumed very low-phosphate diet, phosphate-to-protein ratio (PPR) value of 8 mg/g, experienced an extra reduction of serum phosphorus level by 0.61 mg/dL compared with that of low-phosphate diet, PPR value of 10 mg/g. The aim of the study is to explore the effect of 7-day therapeutic diet intervention on changes of altered mineral metabolism, uremic toxin production, immune dysregulation and inflammation, highlighting the important role of dietary modification in dialysis population. It is to conduct a randomized controlled trial with cross-over design at a hemodialysis unit of tertiary teaching hospital in Northern Taiwan. Subjects with aged older than 20 years, ESKD undergoing maintenance dialysis for more than three months, having adequate dialysis and serum intact parathyroid hormone less than 800 pg/mL will be included. Participants will be randomly assigned into two groups: those in group A will receive study diet for 7 days, followed by 4-week washout period and then receive 7-day usual diet. The opposite order of diets will be prescribed in group B. The study meals are prepared in the hospital cafeteria. Dietary compositions of the study diets were analyzed before the start of the study. The study outcome measures are difference in change-from-baseline values of altered mineral metabolism, uremic toxin production, immune dysregulation and inflammation between the therapeutic diet and the usual diet.
Interventions
OTHERTherapeutic diet
A special healthy diet for dialysis patients
Sponsors
Far Eastern Memorial Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Laboratory technicians who assess the study outcomes will be masked
Intervention model description
A randomized, active-controlled trial with cross-over design
Eligibility
Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Subjects with aged older than 20 years, ESKD undergoing maintenance dialysis for more than three months, having adequate dialysis, serum intact parathyroid hormone less than 800 pg/mL and good dietary compliance
Exclusion criteria
* Patients who meet any of the following criteria will be excluded from the study: 1. Serum albumin level less than 2.5 g/dL 2. Hospitalization within the past 4 weeks 3. Prebiotics, probiotics, symbiotics or antibiotics use within the past 4 weeks 4. History of psychiatric disorders 5. Having mental retardation 6. Those who dislike of the study meals 7. Soft diet requirement 8. Vegetarian
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentrations of intact fibroblast growth factor 23 (pg/mL) | 7 days | Difference in change-from-baseline intact fibroblast growth factor 23 (pg/mL) between therapeutic diet and usual diet |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentrations of phosphate (mg/dL) | 7 days | Difference in change-from-baseline phosphate (mg/dL) between therapeutic diet and usual diet |
| Concentrations of calcium (mg/dL) | 7 days | Difference in change-from-baseline calcium (mg/dL) between therapeutic diet and usual diet |
| Concentrations of intact parathyroid hormone (pg/mL) | 7 days | Difference in change-from-baseline intact parathyroid hormone (pg/mL) between therapeutic diet and usual diet |
| Concentrations of free indoxyl sulfate (mg/L) | 7 days | Difference in change-from-baseline free indoxyl sulfate (mg/L) between therapeutic diet and usual diet |
| Concentrations of free p-cresol sulfate (mg/L) | 7 days | Difference in change-from-baseline free p-cresol sulfate (mg/L) between therapeutic diet and usual diet |
| Concentrations of pre-albumin (g/dL) | 7 days | Difference in change-from-baseline pre-albumin (g/dL) between therapeutic diet and usual diet |
| Concentrations of albumin (g/dL) | 7 days | Difference in change-from-baseline albumin (g/dL) between therapeutic diet and usual diet |
| Concentrations of C-terminal fibroblast growth factor 23 (RU/mL) | 7 days | Difference in change-from-baseline C-terminal fibroblast growth factor 23 (RU/mL) between therapeutic diet and usual diet |
| Absolute number (per μl blood) of CD4+ (cluster of differentiation 4) T cells | 7 days | Difference in change-from-baseline absolute number (per μl blood) of CD4+ T cells between therapeutic diet and usual diet |
| Absolute number (per μl blood) of CD8+ (cluster of differentiation 8) T cells | 7 days | Difference in change-from-baseline absolute number (per μl blood) of CD8+ T cells between therapeutic diet and usual diet |
| Absolute number (per μl blood) of monocytes | 7 days | Difference in change-from-baseline absolute number (per μl blood) of monocytes between therapeutic diet and usual diet |
| Percentage (%) of CD4+ (cluster of differentiation 4) T cells | 7 days | Difference in change-from-baseline percentage (%) of CD4+ (cluster of differentiation 4) T cells between therapeutic diet and usual diet |
| Percentage (%) of CD8+ (cluster of differentiation 8) T cells | 7 days | Difference in change-from-baseline percentage (%) of CD8+ (cluster of differentiation 8) T cells between therapeutic diet and usual diet |
| Percentage (%) of monocytes | 7 days | Difference in change-from-baseline percentage (%) of monocytes between therapeutic diet and usual diet |
| Concentrations of C-reactive protein (mg/dL) | 7 days | Difference in change-from-baseline C-reactive protein (mg/dL) between therapeutic diet and usual diet |
Countries
Taiwan
Outcome results
None listed